CORPORATES Granules India subsidiary receives US FDA EIR with NAI status for Virginia facility Mar 5, 2026
CORPORATES Granules India subsidiary receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets Dec 22, 2025
CORPORATES Granules India subsidiary receives five procedural observations after US FDA GMP inspection Dec 19, 2025
Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY Aug 12, 2025
Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection Aug 1, 2025
Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility Feb 28, 2025